# The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

> **NCT03129555** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Herlev and Gentofte Hospital** · enrollment: 5000 (estimated)

## Conditions studied

- Deep Vein Thrombosis
- Pulmonary Embolism

## Interventions

- **DRUG:** Dabigatran Etexilate Oral Capsule
- **DRUG:** Rivaroxaban Oral Tablet
- **DRUG:** Edoxaban Oral Tablet
- **DRUG:** Apixaban Oral Tablet

## Key facts

- **NCT ID:** NCT03129555
- **Lead sponsor:** Herlev and Gentofte Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129555, "The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03129555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*